Leila Alland was named Chief Medical Officer of Cardiff Oncology, Inc. As of November 6, 2026, Cardiff Oncology, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 2, 2026 to October 27, 2026, naming 2 appointments (Form 8-K, October 27, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Cardiff Oncology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Leila Alland · Role: Chief Medical Officer · 8-K, 2026-10-27
- · In / out: In · Person: Josh Muntner · Role: Chief Financial Officer · Effective: 2026-04-06 · 8-K, 2026-04-09
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-04-02
Cardiff Oncology, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-02 to 2026-10-27. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Cardiff Oncology, Inc. files it.
Also on the record for Cardiff Oncology, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 1.3% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Commodore Capital LP | — | 5%+ stakes | Source |
| July 29, 2025 | Stake report, Schedule 13G, by The Vanguard Group | 5.6% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Cardiff Oncology, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Cardiff Oncology, Inc. and the records around it.
Cardiff Oncology, Inc. elsewhere on the record
Companies that share a holder
- Commodore Capital LP also filed stake reports on 40 other companies: Sagimet Biosciences Inc. (Oct 2026), Surrozen, Inc./DE (Oct 2026), JATT III Acquisition Corp (Sep 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Cardiff Oncology, Inc.
Get an email when Cardiff Oncology, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cardiff Oncology, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cardiff Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cardiff Oncology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-27 | In | Chief Medical Officer | 8-K, 2026-10-27 | ||
| 2026-04-09 | In | Chief Financial Officer | 2026-04-06 | 8-K, 2026-04-09 | |
| 2026-04-02 | Reported | not named in the filing | 8-K, 2026-04-02 |
Who leads Cardiff Oncology, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Medical Officer: Leila Alland, appointed (filed 2026-10-27).
- Chief Financial Officer: Josh Muntner, appointed, effective 2026-04-06 (filed 2026-04-09).
New leaders reset buying decisions — get the Full Report on Cardiff Oncology, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Medical Officer at Cardiff Oncology, Inc., with the record behind each one.
Find candidates like Chief Medical Officer at Cardiff Oncology, Inc.Every change, in the filing's words
Appointed: Leila Alland, Chief Medical Officer
On October 23, 2026, the Company entered into an amended and restated consulting agreement with Leila Alland Md Consultancy LLC (the "Agreement") pursuant to which Dr. Leila Alland will serve as interim Chief Medical Officer of the Company.
- Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
- On October 22, 2026, Dr. Roger Sidhu, Chief Medical Officer of Cardiff Oncology, Inc. (the "Company") separated from the Company in connection with a mutually agreed upon transition.
- The Agreement shall commence on October 23, 2026 and remain in effect until the earlier of (a) April 22, 2027 or (b) the date on which all services have been completed.
- Thereafter, the Agreement may be extended by mutual agreement.
- Dr. Alland will be paid a monthly fee of $35,000 and will devote up to fifty percent (50%) of her professional time as Chief Medical Officer.
- Dr. Alland has served as Chief Medical Officer at several clinical-stage biotechnology companies, including PMV Pharma, a precision oncology company focused on p53; Affimed, an immuno-oncology company; and Tarveda Therapeutics, a company developing targeted drug conjugates.
- Previously, she held leadership positions at AstraZeneca, Bristol Myers Squibb, Novartis and Schering-Plough, where she contributed to the development and approvals of oncology therapies including Tagrisso, Opdivo, Tasigna and Caelyx.
- Dr. Alland currently serves on the Board of Directors of Abeona Therapeutics.
- Dr. Alland received her medical degree from New York University and her bachelor's degree from the University of Pennsylvania.
Appointed: Josh Muntner, Chief Financial Officer, effective 2026-04-06
On April 9, 2026, Cardiff Oncology, Inc. (the "Company") announced that Josh Muntner has been appointed the Company's Chief Financial Officer effective April 6, 2026.
- Mr. Muntner's base salary is $475,000 per year with a 40% annual discretionary bonus.
- In addition, Mr. Muntner was granted non-qualified stock options to purchase 486,650 shares of the Company's common stock as an inducement grant in accordance with Nasdaq Listing Rule 5635(c)(4).
- The option has an exercise price of $1.58 per share, the closing price on the grant date.
- The option vests over four years with 25% vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to Mr. Muntner's continued employment with the Company on such vesting dates.
- In addition, on April 9, 2026, the Company announced that Ajay Aggarwal, MD, MBA has been appointed the Company's Chief Operating Officer, effective April 27, 2026.
- Dr. Aggarwal's base salary is $490,000 with a 40% annual discretionary bonus.
- In addition, Dr. Aggarwal is expected to be granted 400,000 stock options.
- Further, the Company announced on April 9, 2026 that Mani Mohindru, Ph.D. has been appointed as the Company's President and Chief Executive Officer, following her time as Interim Chief Executive Officer.
- Dr. Mohindru's base salary is $655,000 per year with a $100,000 bonus and 55% annual discretionary bonus.
Reported
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
Tools for this story
Each opens in a new tab, filled in for Cardiff Oncology, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.